NCT06958107 LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients
| NCT ID | NCT06958107 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Wake Forest University Health Sciences |
| Condition | Sarcoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2025-08-21 |
| Primary Completion | 2030-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2025-08-21 with a primary completion date of 2030-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research study is to see how well Low Pass Whole Genome Sequencing (LP-WGS) can detect circulating tumor deoxyribonucleic acid (ctDNA) in the blood of participants who have bone or soft tissue sarcoma (type of cancer).
Eligibility Criteria
Inclusion Criteria: 1. Written informed consent or assent when applicable from the participant, LAR, parent or legal guardian and HIPAA authorization for release of personal health information. 2. All ages allowed 3. Suspected or confirmed disease (must meet one of the criteria below): 1. Suspected bone or soft tissue tumor concerning for sarcoma (pending confirmation of sarcoma diagnosis) OR 2. Suspected lipomatous mass concerning for ALT or WDLS with planned surgery OR 3. Confirmed bone or soft tissue sarcoma meeting one of the criteria below: * Non-metastatic/Resectable sarcoma with either planned or currently receiving therapy * Metastatic or unresectable sarcoma, with planned or currently receiving therapy * Non-metastatic sarcoma under surveillance with no more than 1 year from completion of therapy Exclusion Criteria: * none
Contact & Investigator
Johann Hsu, MD
PRINCIPAL INVESTIGATOR
Wake Forest University Health Sciences
Frequently Asked Questions
Who can join the NCT06958107 clinical trial?
This trial is open to participants of all sexes, studying Sarcoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06958107 currently recruiting?
Yes, NCT06958107 is actively recruiting participants. Contact the research team at Megan.Lattanze@advocatehealth.org for enrollment information.
Where is the NCT06958107 trial being conducted?
This trial is being conducted at Charlotte, United States, Winston-Salem, United States.
Who is sponsoring the NCT06958107 clinical trial?
NCT06958107 is sponsored by Wake Forest University Health Sciences. The principal investigator is Johann Hsu, MD at Wake Forest University Health Sciences. The trial plans to enroll 300 participants.